Search research articles
Contact Us
Filters
Showing results (131-140 of 147) with videos related to
Page
of 15
Sort By:
BMJ Open Diabetes Research & Care
|
November 10, 2023
Ethnic disparities in progression rates for sight-threatening diabetic retinopathy in diabetic eye screening: a population-based retrospective cohort study
Abraham Olvera-Barrios, Christopher G Owen, John Anderson, et al.
The British Journal of Ophthalmology
|
October 24, 2023
Two-year recall for people with no diabetic retinopathy: a multi-ethnic population-based retrospective cohort study using real-world data to quantify the effect
Abraham Olvera-Barrios, Alicja R Rudnicka, John Anderson, et al.
JAMA Ophthalmology
|
November 26, 2015
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
John A Wells, Adam R Glassman, Lee M Jampol, et al.
The New England Journal of Medicine
|
July 14, 2022
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Chirag D Jhaveri, Adam R Glassman, Frederick L Ferris, et al.
Ophthalmology Science
|
January 15, 2025
Visual Acuity, Full-field Stimulus Thresholds, and Electroretinography for 4 Years in The Rate of Progression of USH2A-related Retinal Degeneration (RUSH2A) Study
David G Birch, Peiyao Cheng, Maureen G Maguire, et al.
JAMA
|
November 14, 2015
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
, Jeffrey G Gross, Adam R Glassman, et al.
The New England Journal of Medicine
|
February 19, 2015
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
, John A Wells, Adam R Glassman, et al.
Translational Vision Science & Technology
|
November 2, 2020
The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline
David G Birch, Peiyao Cheng, Jacque L Duncan, et al.
American Journal of Ophthalmology
|
March 8, 2025
Corrigendum to "Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity" [Am J Ophthalmol 2020;219:87-100]
Jacque L Duncan, Wendi Liang, Maureen G Maguire, et al.
American Journal of Ophthalmology
|
August 3, 2025
Corrigendum to "Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity." Am J Ophthalmol. 2020; 219:87-100
Jacque L Duncan, Wendi Liang, Maureen G Maguire, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 147) with videos related to
Sort By:
Page
of 15
BMJ Open Diabetes Research & Care
|
November 10, 2023
Ethnic disparities in progression rates for sight-threatening diabetic retinopathy in diabetic eye screening: a population-based retrospective cohort study
Abraham Olvera-Barrios, Christopher G Owen, John Anderson, et al.
The British Journal of Ophthalmology
|
October 24, 2023
Two-year recall for people with no diabetic retinopathy: a multi-ethnic population-based retrospective cohort study using real-world data to quantify the effect
Abraham Olvera-Barrios, Alicja R Rudnicka, John Anderson, et al.
JAMA Ophthalmology
|
November 26, 2015
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
John A Wells, Adam R Glassman, Lee M Jampol, et al.
The New England Journal of Medicine
|
July 14, 2022
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Chirag D Jhaveri, Adam R Glassman, Frederick L Ferris, et al.
Ophthalmology Science
|
January 15, 2025
Visual Acuity, Full-field Stimulus Thresholds, and Electroretinography for 4 Years in The Rate of Progression of USH2A-related Retinal Degeneration (RUSH2A) Study
David G Birch, Peiyao Cheng, Maureen G Maguire, et al.
JAMA
|
November 14, 2015
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
, Jeffrey G Gross, Adam R Glassman, et al.
The New England Journal of Medicine
|
February 19, 2015
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
, John A Wells, Adam R Glassman, et al.
Translational Vision Science & Technology
|
November 2, 2020
The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline
David G Birch, Peiyao Cheng, Jacque L Duncan, et al.
American Journal of Ophthalmology
|
March 8, 2025
Corrigendum to "Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity" [Am J Ophthalmol 2020;219:87-100]
Jacque L Duncan, Wendi Liang, Maureen G Maguire, et al.
American Journal of Ophthalmology
|
August 3, 2025
Corrigendum to "Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity." Am J Ophthalmol. 2020; 219:87-100
Jacque L Duncan, Wendi Liang, Maureen G Maguire, et al.
Page
of 15